Page 71 of 345: studies 701 to 710 of 3,446, newest first. Back to the MDMA overview
Routledge eBooks June 14, 2018 A. C. Parrott 7 citations
This chapter aims to critically evaluate methamphetamine derivative (MDMA) proposal from a psychobiological perspective. It overviews the early years of MDMA-assisted psychotherapy up to 1986, when MDMA was scheduled as a Class A drug. The chapter also reviews the psychobiology of MDMA, focusing on its diverse mood effects, while also covering other psychobiological functions. It presents a...
June 14, 2018 Carl Alexander Roberts, Catharine Montgomery 1 citation
Ecstasy/3,4 Methylenedioxymethamphetamine is a popular recreational drug that is a potent indirect monoaminergic agonist that has structural similarities to mescaline and amphetamine. It is presumed that interfering with regulatory serotonin signalling with chronic ecstasy use may result in psychobiological harm. This chapter reviews evidence from studies assessing mood, cognition, pain, sleep...
British journal of nursing June 14, 2018 Nicola Davies, William English, Johann Grundlingh
Since the 1980s, methylenedioxymethamphetamine (MDMA) has been a popular recreational drug, used particularly among those who attend raves and nightclubs. Over the past 3 years, the popularity of this drug has once again increased and there has been an associated rise in deaths. The pathophysiology of MDMA toxicity is complex and much remains to be understood. This article aims to increase...
Progress in Neuro-Psychopharmacology and Biological Psychiatry June 8, 2018 Allison A. Feduccia, Michael C Mithoefer 213 citations
MDMA-assisted psychotherapy for treatment of PTSD has recently progressed to Phase 3 clinical trials and received Breakthrough Therapy designation by the FDA. MDMA used as an adjunct during psychotherapy sessions has demonstrated effectiveness and acceptable safety in reducing PTSD symptoms in Phase 2 trials, with durable remission of PTSD diagnosis in 68% of participants. The underlying...
Substance Use & Misuse June 7, 2018 Khary K. Rigg, Maayan Lawental
The research literature on MDMA (ecstasy/molly) use has largely relied on samples of ravers/club-goers, gay men, and international populations (e.g., United Kingdom, Australia). As a result, very little is known about MDMA use among African Americans. This study aimed to address this gap by adding to the limited amount of research with this population. The goal of this study was to identify and...
The Lancet Psychiatry June 1, 2018 A. Cipriani, P. Cowen
Published online at: https://doi.org/10.1016/S2215-0366(18)30170-6 Eligible users can access the full text via NHS OpenAthens at [https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2215036618301706] (login required).
Cutaneous and Ocular Toxicology June 2018 Xin Liu, Li-Hui Zhan, Xiao-Hong Sun et al.
The abuse of 3,4-methylenedioxymethamphetamine (MDMA), a psychedelic drug, can lead to a variety of disorders in neural system, including the death of retinal neural cells. MDMA at lower doses does not cause obvious cytotoxicity to photoreceptor cells, indicating potential indirect mechanisms which have not yet been elucidated. This study investigated the effect of MDMA at nontoxic...
Journal of Medical Case Reports May 25, 2018 Kaeley Kaplan, Fiona Kurtz, Kelly Serafini
In this report, we describe a case of a patient with substance-induced anxiety disorder occurring after a single dose of 3,4-methylenedioxymethamphetamine. Furthermore, we describe the use and efficacy of the Primary Care Behavioral Health model, a collaborative approach to integrative primary mental health care, in evaluating and treating this rare mental health disorder. Three days following...
Journal watch May 18, 2018 Peter Roy‐Byrne
Current treatments for chronic post-traumatic stress disorder (PTSD) have limited efficacy. In a two-stage, phase 2 study (funded by a nonprofit
Journal of Psychopharmacology May 7, 2018 Balázs Szigeti, Adam Winstock, David Erritzøe et al. 17 citations
BACKGROUND: Neuroimaging studies imply that the regular use of ±3,4-methylenedioxymethamphetamine (MDMA), the major constituent of ecstasy pills, alters the brain's serotonergic system in a dose-dependent manner. However, the relevance of these findings remains unclear due to limited knowledge about the ecstasy/MDMA use pattern of real-life users. AIMS: We examined the representativeness of...